Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Rhea-AI Summary

Arcutis (Nasdaq: ARQT) outlined 2026 strategic priorities focused on expanding the commercial footprint of ZORYVE and advancing its pipeline. Management reiterated full-year ZORYVE net product sales guidance of $455–$470 million and plans a targeted ~20% dermatology sales force expansion. Key development milestones include topline INTEGUMENT-INFANT Phase 2 results in Q1 2026 and an expected sNDA submission in Q3 2026 for ZORYVE cream 0.05% in infants; an FDA PDUFA target action date of June 29, 2026 for the sNDA for ZORYVE cream 0.3% in ages 2–5; Phase 2 proof‑of‑concept trials in vitiligo and hidradenitis suppurativa with program decisions in Q4 2026 and Q1 2027; and initiation of Phase 1 enrollment for ARQ-234 in Q1 2026. The company cited a transition to positive cash flows to fund growth and pipeline investment.

Positive

• 2026 ZORYVE net product sales guidance of $455–$470 million
• Targeted ~20% expansion of dermatology sales force to increase prescriber reach
• PDUFA target action date set for June 29, 2026 for pediatric plaque psoriasis sNDA
• Begin Phase 1 enrollment for ARQ-234 in Q1 2026

Negative

• Topline infant Phase 2 results for ZORYVE expected in Q1 2026 with sNDA submission planned in Q3 2026 (timing risk)
• Decisions on ZORYVE program advancement in vitiligo and hidradenitis suppurativa deferred to Q4 2026 and Q1 2027

News Market Reaction – ARQT

-5.10%

41 alerts

-5.10% News Effect

-4.4% Trough in 4 hr 48 min

-$175M Valuation Impact

$3.26B Market Cap

1.2x Rel. Volume

On the day this news was published, ARQT declined 5.10%, reflecting a notable negative market reaction. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $175M from the company's valuation, bringing the market cap to $3.26B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

2026 net product sales guidance: $455–$470 million Dermatology sales force expansion: ~20% ZORYVE cream dose: 0.05% +5 more

8 metrics

2026 net product sales guidance $455–$470 million Full-year ZORYVE net product sales guidance for 2026

Dermatology sales force expansion ~20% Targeted expansion of dermatology sales force

ZORYVE cream dose 0.05% INTEGUMENT-INFANT Phase 2 study dose for infants

Infant age range 3 months to <24 months INTEGUMENT-INFANT Phase 2 atopic dermatitis population

PDUFA target date June 29, 2026 FDA review of ZORYVE cream 0.3% in plaque psoriasis (ages 2–5)

ZORYVE cream dose 0.3% sNDA for plaque psoriasis in children ages 2–5

Vitiligo decision timing Q4 2026 Decision on advancement of ZORYVE foam 0.3% in vitiligo

Hidradenitis suppurativa decision Q1 2027 Decision on advancement of ZORYVE foam 0.3% in HS

Market Reality Check

Price: $23.60 Vol: Volume 1,704,355 vs 20-da...

normal vol

$23.60 Last Close

Volume Volume 1,704,355 vs 20-day average 1,897,183 (relative volume 0.9x). normal

Technical Price 28.22 is trading above 200-day MA at 18.78 while down 5.56% on the day.

Peers on Argus

ARQT fell 5.56% while close peers like APGE, TARS, AGIO, IRON, and TVTX also tra...

1 Up

ARQT fell 5.56% while close peers like APGE, TARS, AGIO, IRON, and TVTX also traded down modestly (from about -0.49% to -2.7%). Momentum scanner only flagged BEAM up 9.62% with no news, supporting a stock-specific move rather than a coordinated sector rotation.

Common Catalyst Some biotech peers, such as AGIO, also issued 2026 strategic priority updates, but peer price reactions were not provided.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Board changes	Positive	-4.1%	New director appointment and founder’s transition to consulting role.
Nov 17	Regulatory update	Positive	+4.7%	FDA acceptance of sNDA for ZORYVE 0.3% in children ages 2–5.
Nov 13	Clinical trial progress	Positive	-2.5%	Completion of enrollment in INTEGUMENT-INFANT Phase 2 study.
Nov 07	Equity inducements	Neutral	-2.0%	Disclosure of 51,000 RSUs granted to new hires under inducement plan.
Nov 04	Clinical data	Positive	-3.0%	Publication of positive long-term safety and efficacy data for ZORYVE foam.

Pattern Detected

Positive or growth-oriented news has frequently been followed by negative 24-hour price reactions, with only one clearly positive alignment in the recent set.

Recent Company History

Over the past few months, Arcutis has focused on expanding the ZORYVE franchise and strengthening governance. In Oct–Nov 2025, it advanced pediatric and seborrheic dermatitis programs and secured FDA acceptance of a supplemental NDA with a June 29, 2026 PDUFA date. Board changes were announced on Dec 8, 2025, and equity inducement grants were disclosed in early November. Despite generally constructive operational updates, several of these events were followed by short-term share price declines, similar to the pre-news pullback seen today.

Market Pulse Summary

The stock moved -5.1% in the session following this news. A negative reaction despite detailed 2026 ...

Analysis

The stock moved -5.1% in the session following this news. A negative reaction despite detailed 2026 growth and pipeline milestones fits a pattern where several positive ZORYVE updates were followed by declines of roughly 2–4%. Today’s -5.56% move came even as management guided to $455–$470 million in 2026 net product sales and outlined multiple upcoming readouts and decisions. Past behavior suggests that good news has not always translated into sustained gains, leaving room for position rebalancing or profit-taking around such catalysts.

Key Terms

phase 2, phase 1, supplemental new drug application, snda, +4 more

8 terms

phase 2 medical

"ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativa"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 1 medical

"Begin enrolling patients in the Phase 1 study of ARQ-234"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

supplemental new drug application regulatory

"submission of a supplemental New Drug Application (sNDA) in the third quarter of 2026"

A supplemental new drug application is a request submitted to regulatory authorities to make changes to an existing approved medication, such as adding new uses, strengths, or formulations. For investors, it signals that a pharmaceutical company is seeking approval for new product developments or expanded applications, which can impact the company's future sales, market potential, and stock value.

snda regulatory

"FDA review ongoing of sNDA for ZORYVE cream 0.3%"

A SNDA (Subordination, Non‑Disturbance and Attornment Agreement) is a legal pact among a property owner’s lender, the owner’s tenants, and sometimes the landlord that sets who keeps lease rights if the property is sold or a mortgage is enforced. Think of it as a rulebook that decides whether a tenant can stay and keep paying rent or must answer to a new owner after a foreclosure. For investors, an SNDA matters because it protects predictable rental income, clarifies who has priority on claims against a property, and therefore affects a property’s value and the security of related loans.

u.s. food and drug administration regulatory

"U.S. Food and Drug Administration (FDA) review ongoing of sNDA"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

prescription drug user fee act regulatory

"Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026"

A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.

pdufa regulatory

"Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026"

PDUFA, short for the Prescription Drug User Fee Act, is a law that allows drug companies to pay fees to the government to speed up the review process for new medicines. This helps bring important drugs to market more quickly, which can impact their availability and pricing. For investors, PDUFA timelines can influence the timing of a drug’s approval and potential market success.

checkpoint agonist medical

"a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor"

A checkpoint agonist is a drug that stimulates specific immune-control receptors to strengthen or direct the body’s immune response, often used to make immune cells attack disease more effectively. Think of it like pressing an accelerator on immune cells rather than cutting a brake; for investors, these drugs matter because they are a distinct class of therapies with potential for strong clinical benefit, high development risk, regulatory scrutiny, and significant commercial upside if they succeed.

AI-generated analysis. Not financial advice.

• Continued strong growth of ZORYVE^® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million
• Advancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativa
• Initiation of clinical development program for ARQ-234 in atopic dermatitis
• Transition to positive cash flows enables investment to both accelerate growth of ZORYVE franchise and advance pipeline

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced its strategic priorities for 2026.

“2025 was a transformative year as we solidified ZORYVE’s position as an advanced targeted topical with the potential to redefine the standard of care for chronic inflammatory skin diseases,” said Frank Watanabe, president and chief executive officer of Arcutis. “In 2026, we will build on this momentum by driving ZORYVE growth across approved indications and investing in our commercial capabilities to accelerate the conversion from topical corticosteroids. At the same time, we will advance our innovative pipeline, including ZORYVE life cycle initiatives and ARQ-234, our biologic for atopic dermatitis. With strong operating leverage, we are well positioned to pursue new opportunities and reinforce our leadership in medical dermatology drug development and commercialization.”

2026 Strategic Priorities

Grow our core ZORYVE business as we establish ZORYVE as the foundational therapy for adults and children who need long-term therapeutic solutions for managing their plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.

• Sustainable momentum of ZORYVE franchise with 2026 net product sales expected in the $455–$470 million range.
• Targeted ~20% expansion of dermatology sales force to optimize prescriber targeting and call frequency, deepening adoption of ZORYVE.

• Continued label expansion efforts to progress ZORYVE for the treatment of pediatric patients:
  • Expect to announce topline results from INTEGUMENT-INFANT Phase 2 study of ZORYVE cream 0.05% in infants age 3 months to less than 24 months in the first quarter of 2026 and submission of a supplemental New Drug Application (sNDA) in the third quarter of 2026.
  • U.S. Food and Drug Administration (FDA) review ongoing of sNDA for ZORYVE cream 0.3% for the treatment of plaque psoriasis in children ages 2-5; Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026.
    

Expand the ZORYVE franchise into additional indications through strategic life cycle management beginning with proof-of-concept studies in vitiligo and hidradenitis suppurativa.

• Expect to report decision on program advancement for investigational ZORYVE foam 0.3% for the treatment of vitiligo in the fourth quarter of 2026.
• Expect to report decision on program advancement for investigational ZORYVE foam 0.3% for the treatment of hidradenitis suppurativa in the first quarter of 2027.

Build our pipeline by advancing innovative medicines for patients, leveraging industry-leading clinical development and commercialization capabilities that we have developed at Arcutis.

• Begin enrolling patients in the Phase 1 study of ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor, being developed as a potential biologic treatment for atopic dermatitis, in the first quarter of 2026.
  

About Arcutis 
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

INDICATIONS
ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding the potential results of clinical trials and associated timelines, and statements regarding forward-looking financial results. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition, and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

FAQ

What is Arcutis (ARQT) 2026 net sales guidance for ZORYVE?

Arcutis reiterated 2026 ZORYVE net product sales guidance of $455–$470 million.

When is the FDA PDUFA target action date for ZORYVE cream 0.3% (ages 2–5) for ARQT?

The PDUFA target action date for the sNDA is June 29, 2026.

When will Arcutis report topline results from the INTEGUMENT-INFANT Phase 2 study for ARQT?

Topline results from the INTEGUMENT-INFANT Phase 2 study are expected in Q1 2026.

What are Arcutis plans for expanding the ZORYVE commercial team in 2026?

Arcutis plans a targeted approximately 20% expansion of its dermatology sales force in 2026.

When will Arcutis begin clinical development of ARQ-234 (ARQT)?

Arcutis intends to begin enrolling patients in the Phase 1 study of ARQ-234 in Q1 2026.

When will Arcutis decide on advancing ZORYVE for vitiligo and hidradenitis suppurativa?

A decision on the vitiligo program is expected in Q4 2026 and on hidradenitis suppurativa in Q1 2027.